Skip to main content
Clinical Trials/NCT03209804
NCT03209804
Completed
Not Applicable

Surgical Management of Cerebral Arteriovenous Malformations Within Hybrid Operation Room

Ministry of Science and Technology of the People´s Republic of China4 sites in 1 country519 target enrollmentJune 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Intracranial Arteriovenous Malformations
Sponsor
Ministry of Science and Technology of the People´s Republic of China
Enrollment
519
Locations
4
Primary Endpoint
Instant residual rate of AVMs
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

To evaluate the clinical benefits and risks of hybrid operating techniques in management of cerebral arteriovenous malformations.

Detailed Description

Purpose: Have an evaluation of clinical benefits and risks of hybrid operating techniques in management of cerebral arteriovenous malformations(AVMs). Meanwhile, as a new cooperative interventional modality, optimized workflows, technical key knots and operation routines will be explored in the study. Objects: Patients with cerebral arteriovenous malformations, coincident with inclusion and exclusion criterion and admitted in participating organizations. Methods: Patients will be distributed into 2 groups, including traditional therapy group(control group) and hybrid operating group(trial group), and conduct with traditional neurosurgical management or one-stage hybrid operating management correspondingly. Residual rate of AVM is considered to be the primary observing indicator, and morbidity rate of post-operative complications, post-operative mortality rate, and morbidity rate of neural functional deterioration are secondary indicators.The information of operations will be recorded in detail as evidence of optimization of workflow and technical key knots.

Registry
clinicaltrials.gov
Start Date
June 2016
End Date
January 16, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Ministry of Science and Technology of the People´s Republic of China
Responsible Party
Principal Investigator
Principal Investigator

Shuo Wang

liuxingju

Beijing Tiantan Hospital

Eligibility Criteria

Inclusion Criteria

  • newly ruptured AVM with stable hematoma, selective operation is practical;
  • with rupture history;
  • recurrent epilepsy, failed in AED management;
  • giant AVM with deterioration of neurological functions;
  • 1-4 grade AVM (Spetzler-Martin grading system) with no symptom and not located in eloquent area.

Exclusion Criteria

  • \>70 in age, with low rupture risk;
  • newly ruptured AVM with unstable hematoma, engaged in emergency operation;
  • ≥5 grade in Spetzler-Martin grading system;
  • AVM located in hypothalamus, brainstem, cerebellopontine angle;
  • cannot tolerant the operation;
  • patient or relative refuses to participate the trail.

Outcomes

Primary Outcomes

Instant residual rate of AVMs

Time Frame: up to 1 week after operation

The instant post-operative residual rate of AVMs

6 months' residual rate of AVMs

Time Frame: the date of the 6th month after operation, ±1 week

6 months' residual rate after AVM operation

3 months' residual rate of AVMs

Time Frame: the date of 3rd month after operation, ±1 week

3 months' residual rate after AVM operation

1 year's residual rate of AVMs

Time Frame: the date of the 12th month after operation, ±1 week

1 year's residual rate after AVM operation

Secondary Outcomes

  • Morbidity rate of post-operative complications(7 days after operation)
  • Morbidity rate of neural functional deterioration-1 week after operation(1 week after operation)
  • Morbidity rate of neural functional deterioration-12 months after operation(the 12th month after operation, ±1 week)
  • Post-operative mortality rate(48 hours after operation)
  • Morbidity rate of neural functional deterioration-48 hours after operation(the assessing time points is 48 hours after operation)
  • Morbidity rate of neural functional deterioration-3 months after operation(the 3rd month after operation, ±1 week)
  • Morbidity rate of neural functional deterioration-6 months after operation(the 6th month after operation, ±1 week)

Study Sites (4)

Loading locations...

Similar Trials